CytomX Therapeutics

(NASDAQ) CTMX

Current Price$4.05

Market Cap$890.65M

Since IPO (2015)-67%

5 Year-57%

1 Year+482%

1 Month-9%

CytomX Therapeutics Financials at a Glance

Market Cap

$890.65M

Revenue (TTM)

$76.20M

Net Income (TTM)

$17.37M

EPS (TTM)

$0.01

P/E Ratio

452.75

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$4.05

Volume

309,051.027

Open

$4.09

Price

$4.05

Volume

309,051.027

Open

$4.09

Previous Close

$4.12

Daily Range

$4.00 - $4.13

52-Week Range

$0.63 - $8.21

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$4.05

Volume

309,051.027

Open

$4.09

Previous Close

$4.12

Daily Range

$4.00 - $4.13

52-Week Range

$0.63 - $8.21

CTMX News

investor trader chart graph stock point growth profit loss-1200x800-5b2df79

Small Cap or Megacap: Which Healthcare Stock Is Right for You?

Jack DelaneyApr 22, 2026

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

Howard SmithMar 16, 2026

Person in a lab gazing into a microscope

Is This Innovative Cancer Research Biotech a Buy?

Zhiyuan SunMay 20, 2020

CTMX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CytomX Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Sean A. McCarthy, PhD, MBA

Website

www.cytomx.com

Headquarters

South San Francisco, CA 94080, US

CTMX Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-29%

Net Income Margin

-23%

Return on Equity

-35%

Return on Capital

-21%

Return on Assets

-11%

Earnings Yield

0.22%

Dividend Yield

0.00%

Payout Ratio

-17.28%

Stock Overview

Market Cap

$890.65M

Shares Outstanding

216.18M

Volume

309.05K

Avg. Volume

6.78M

Financials (TTM)

Gross Profit

$76.20M

Operating Income

$19.56M

EBITDA

$18.19M

Operating Cash Flow

$75.59M

Capital Expenditure

$220.00K

Free Cash Flow

$75.81M

Cash & ST Invst.

$137.05M

Total Debt

$4.24M

CytomX Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$663.00K

-98.3%

Gross Profit

$153.00K

-99.6%

Gross Margin

23.08%

N/A

Market Cap

$890.65M

N/A

Market Cap/Employee

$7.48M

N/A

Employees

119

N/A

Net Income

$26.51M

-240.4%

EBITDA

$27.42M

-251.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$132.81M

+45.6%

Accounts Receivable

$2.51M

-19.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$4.24M

-17.6%

Return on Assets

-11.39%

N/A

Return on Invested Capital

-21.12%

N/A

Free Cash Flow

$23.44M

-17.3%

Operating Cash Flow

$23.24M

-16.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MGTXMeiraGTx Holdings plc

MGTXMeiraGTx Holdings plc$8.82-2.88%

MBXMBX Biosciences, Inc. Common Stock

MBXMBX Biosciences, Inc. Common Stock$28.74-1.03%

ATXSAstria Therapeutics, Inc.

ATXSAstria Therapeutics, Inc.$12.58+0.00%

IOVAIovance Biotherapeutics, Inc.

IOVAIovance Biotherapeutics, Inc.$3.29-2.81%

MLTXMoonLake Immunotherapeutics

MLTXMoonLake Immunotherapeutics$16.32-2.04%

AVBPArriVent BioPharma, Inc. Common Stock

AVBPArriVent BioPharma, Inc. Common Stock$29.71-1.10%

DNAGinkgo Bioworks Holdings, Inc.

DNAGinkgo Bioworks Holdings, Inc.$7.43-5.29%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.94-0.13%

KALVKalVista Pharmaceuticals

KALVKalVista Pharmaceuticals$26.70+0.39%

ONDSOndas

ONDSOndas$9.46-0.10%

POETPoet Technologies

POETPoet Technologies$7.04-0.12%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.86-0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$60.93+0.00%

VALEVale

VALEVale$15.99-0.05%

Questions About CTMX

What is the current price of CytomX Therapeutics?

CytomX Therapeutics is trading at $4.05 per share.

What is the 52-week range for CytomX Therapeutics?

Over the past 52 weeks, CytomX Therapeutics has traded between $0.63 and $8.21.

How much debt does CytomX Therapeutics have?

As of the most recent reporting period, CytomX Therapeutics reported total debt of $4.24M.

How much cash does CytomX Therapeutics have on hand?

CytomX Therapeutics reported $12.67M in cash and cash equivalents in its most recent financial results.

What is CytomX Therapeutics’s dividend yield?

CytomX Therapeutics does not currently have a dividend yield.

CytomX Therapeutics

CytomX Therapeutics Financials at a Glance

CTMX News

Small Cap or Megacap: Which Healthcare Stock Is Right for You?

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

Why CytomX Therapeutics Stock Was Skyrocketing This Week

CytomX (CTMX) Q2 Revenue Drops 26%

Why CytomX Therapeutics Stock Is Crashing Today

Is This Innovative Cancer Research Biotech a Buy?

CTMX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About CytomX Therapeutics

CTMX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

CytomX Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CTMX

What is the current price of CytomX Therapeutics?

What is the 52-week range for CytomX Therapeutics?

How much debt does CytomX Therapeutics have?

How much cash does CytomX Therapeutics have on hand?

What is CytomX Therapeutics’s dividend yield?

Premium Investing Services